Loading...
•
Dec 31, 2024
•/
Stevanato Group Q4 2024 Earnings Report
Stevanato Group reported a 3% revenue increase in Q4 2024, driven by strong demand for high-value solutions.
Key Takeaways
Stevanato Group reported Q4 2024 revenue of €330.6 million, a 3% increase year-over-year. The Biopharmaceutical and Diagnostic Solutions segment grew 7%, offsetting a 16% decline in the Engineering segment. Gross profit margin declined to 29.7%, impacted by vial destocking, while operating profit margin improved to 20.2%. Adjusted EPS was €0.19, reflecting cost management initiatives and strong performance in high-value solutions.
Q4 revenue grew 3% year-over-year to €330.6 million.
Biopharmaceutical and Diagnostic Solutions segment increased 7%, offsetting a 16% decline in Engineering.
Gross profit margin declined by 210 basis points to 29.7%, impacted by vial destocking.
Adjusted diluted EPS increased to €0.19, driven by cost controls and strong demand for syringes.
Revenue by Segment
Forward Guidance
Stevanato Group expects continued revenue growth in FY 2025, driven by demand for high-value solutions and ongoing capacity expansion. Cost management initiatives will continue to support margin improvements.
Positive Outlook
- Projected FY 2025 revenue between €1,160 million and €1,190 million.
- Adjusted EBITDA forecasted to range from €293 million to €306.3 million.
- Adjusted diluted EPS expected to be between €0.51 and €0.55.
- Continued demand growth in high-value syringes and biologics-related products.
- Operational efficiencies and cost-saving initiatives to improve margins.
Challenges Ahead
- Engineering segment challenges expected to persist in the near term.
- Vial destocking effects may continue to impact revenue mix.
- Higher capital expenditures expected due to facility expansions.
- Macroeconomic uncertainties could affect customer demand.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...